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Summary	
Low	mannose‐binding	lectin	concentration,	but	not	genotype,	was	associated	with	
disease	recurrence	in	a	large	prospective	cohort	of	patients	with	Clostridium	difficile	
infection	(CDI). 
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Abstract	
Background:	Mannose‐binding	lectin	(MBL)	plays	a	key	role	in	the	activation	of	the	
lectin‐complement	pathway	of	innate	immunity	and	its	deficiency	has	been	linked	with	
several	acute	infections.	However,	its	role	in	predisposing	to,	or	modulating	disease	
severity	in,	Clostridium	difficile	infection	(CDI)	has	not	been	investigated.			
Methods:	We	prospectively	recruited	308	CDI	cases	and	145	controls	patients	with	
antibiotic‐associated	diarrhea	(AAD).	CDI	outcome	measures	were	disease	severity,	
duration	of	symptoms,	30‐day	mortality	and	90‐day	recurrence.		Serum	concentrations	
of	MBL	were	determined	using	a	commercial	ELISA	assay	transferred	to	an	
electrochemiluminescence	(ECL)‐based	platform.	MBL2	polymorphisms	were	typed	
using	a	combination	of	pyrosequencing	and	Taqman	genotyping	assays.		
Results:	The	frequency	of	the	MBL2	genetic	variants	was	similar	to	that	reported	in	
other	Caucasian	populations.		MBL	serum	concentrations	in	CDI	and	AAD	subjects	were	
determined	by	MBL2	exonic	variants	B,	C	and	D	and	the	haplotypes	(LYPB,	LYQC	and	
HYPD).		There	was	no	difference	in	either	MBL	concentrations	or	genotypes	between	
CDI	cases	and	AAD	controls.		MBL	concentration,	but	not	genotype,	was	a	determinant	of	
CDI	recurrence	(odds	ratios	of	3.18	(95%	CI	1.40‐7.24)	and	2.61	(95%	CI	1.35‐5.04))	at	
the	<50	ng/ml	and	<100	ng/ml	cut‐off	points,	respectively;	p<0.001).		However,	neither	
MBL	concentration	nor	MBL2	genotype	was	linked	with	the	other	CDI	outcomes.	
Conclusion:	Serum	MBL	concentration	did	not	differentiate	between	CDI	cases	and	AAD		
controls,	but	amongst	CDI	cases,	MBL	concentration,	but	not	genotype,	was	associated	
with	CDI	recurrence,	indicating	MBL	acts	as	a	modulator	of	disease,	rather	than	a	
predisposing	factor.	
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Introduction	
The	initiation	and	propagation	of	inflammatory	cascades	is	an	essential	housekeeping	
property	of	the	innate	immune	response	during	infections.	Mannose‐binding	lectin	
(MBL)	activates	the	lectin‐complement	pathway	of	innate	immunity	through	binding	to	
repetitive	sugar	arrays	on	microbial	surfaces	[1].	MBL	is	also	a	potent	regulator	of	
inflammatory	pathways:	it	can	modulate	phagocyte	interaction	with	mucosal	organisms	
at	the	site	of	infection	[2],	and	interacts	with	other	components	of	the	innate	immune	
system	such	as	toll‐like	receptors	[3].		
Low	MBL	concentrations	have	been	associated	with	increased	susceptibility	to	
infections	in	both	animal	models	and	humans	[4,	5],	as	well	as	with	poor	disease	
prognosis	[1].	The	modulation	of	disease	severity	is	partly	thought	to	be	through	a	
complex,	dose‐dependent	influence	on	cytokine	production	[6].	Serum	MBL	
concentrations	range	from	negligible	to	as	high	as	10,000	ng/ml	[7‐9];	this	varies	with	
ethnicity	and	with	the	screening	method	adopted	[10].	
MBL	secretion	in	humans	is	dependent	on	the	MBL2	genetic	architecture	[11,	12].	To	
date,	57	genetic	variants	have	been	identified	within	the	entire	MBL2	gene	(SNP	
database,	Build	140),	with	only	six	of	them	known	to	affect	secretion	and/or	function	of	
the	encoded	protein	(Figure	1)	[8,	13].	The	mutated	alleles	B,	C	or	D	are	collectively	
termed	O	and	their	correspondent	wild‐type	alleles	are	jointly	referred	to	as	variant	A,	
with	the	presence	of	any	given	O	variant	(in	either	the	heterozygous	or	homozygous	
state)	resulting	in	MBL	deficiency	[8,	13].	The	existence	of	strong	linkage	disequilibrium	
(LD)	between	the	promoter	and	structural	gene	variants	means	that	only	seven	common	
haplotypes	(out	of	a	possible	64),	which	may	affect	serum	concentrations,	have	been	
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described:	HYPA,	LYQA,	LYPA,	LXPA,	HYPD,	LYPB	and	LYQC	[14,	15].		HYPD,	LYPB	and	
LYQC	lead	to	the	production	of	unstable	ligands	with	shorter	half‐lives	that	are	easily	
degraded	to	lower	oligomeric	forms.		Studies	that	have	evaluated	both	genetic	mutations	
and	serum	concentrations	in	Whites	are	summarized	in	Supplementary	Table	1.		
Clostridium	difficile	is	an	opportunistic	spore‐forming	bacterium	that	can	effectively	
colonise	the	intestinal	tract	following	antibiotic‐driven	dysbiosis.	Clostridium	difficile	
infection	(CDI)	is	the	result	of	intense	colonic	inflammation	caused	by	the	release	of	
potent	enterotoxins.	Research	into	host	biomarkers	for	CDI	has	focused	on	mediators	of	
inflammation	in	the	gut	such	as	faecal	interleukin‐8	[16],	lactoferrin	[16]	and	
calprotectin	[17],	and	linked	them	with	disease	severity	[16,	18].		More	recently,	both	
serum	interleukin‐23	and	procalcitonin	have	also	been	proposed	as	potential	
biomarkers	for	CDI	severity	[19,	20].	However,	the	role	of	these	biomarkers	in	the	
stratification	of	problematic	CDI	patients	remains	unclear,	and	thus	remains	an	
important	area	of	research.	Additionally,	several	clinical	prediction	rules	have	been	
proposed	for	the	evaluation	of	CDI	outcomes	[21‐23],	but	none	have	gained	widespread	
clinical	acceptance.		
To	date,	there	have	been	no	studies	on	the	role	of	either	MBL	levels	or	MBL2	genetic	
variants	with	CDI,	possibly	because	MBL	is	not	thought	to	bind	to	the	surface	of	C.	
difficile	[24].	However,	there	is	growing	evidence	for	an	association	between	MBL	and	
major	modulators	of	inflammation,	such	as	toll‐like	receptors	and	CRP,	both	of	which	
have	been	associated	with	CDI	[25,	26].	Therefore,	we	sought	to	investigate	the	role	of	
MBL	in	a	prospective	cohort	of	CDI	cases	and	inpatient	controls.	
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Methods	
Cohort	
A	cohort	of	453	inpatients	was	consecutively	recruited	from	a	large	hospital	setting	in	
Merseyside,	UK.	Patients	were	eligible	for	inclusion	if	they	had	healthcare‐associated	
diarrhea,	defined	as	≥3	liquid	stools	passed	in	the	24	hours	preceding	assessment,	an	
onset	after	being	in	hospital	for	over	48	hours	and	recent	exposure	to	either	
antimicrobials	and/or	proton	pump	inhibitors.	Using	criteria	previously	described	[27],	
308	CDI	cases	and	145	controls	with	antibiotic‐associated	diarrhea	(AAD)	were	
classified	based	on	toxin	ELISA	test	(TOX	A/B	II,	Techlab,	Blacksburg,	USA),	
microbiological	culture	and	clinical	diagnosis	made	by	independent	clinicians.	PCR	
ribotyping	and	multiplex	PCR	were	performed	to	determine	strains	types	and	the	
toxigenic	nature	of	the	isolates	[28].		
Blood	and	fecal	specimens	were	collected	from	patients	at	study	entry,	of	whom	98%	
were	Whites.	Relevant	information	on	demographics,	admission	and	clinical	history	was	
collected	for	each	patient.	Ethical	approval	was	obtained	from	the	Liverpool	Research	
Ethics	Committee	(reference	number	08/H1005/32)	and	each	patient	provided	written	
informed	consent	prior	to	recruitment.		
Definition	of	outcomes	
Cases	and	controls	were	defined	as	described	above.	The	severity	of	CDI	symptoms	was	
assessed	at	baseline	by	research	nurses	using	the	guidelines	proposed	by	Public	Health	
England	[29],	which	we	adjusted	to	incorporate	a	more	stringent	white	blood	cell	count	
cut‐off	of	>20	x109/L	whilst	also	replacing	acute	rising	creatinine	with	a	Glomerular	
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Filtration	Rate	(eGFR)	of	<30ml/min	at	the	time	of	diagnosis.	Duration	of	symptoms	
from	CDI	diagnosis	was	recorded	from	the	date	patients	tested	positive	and	then	
dichotomised	into	episodes	lasting	more	or	less	than	10	days.	Mortality	was	actively	
monitored	for	a	period	of	30	days	and	recurrent	CDI	was	defined	as	the	development	of	
subsequent	CDI	episodes	up	to	a	period	of	90	days	following	treatment	of	the	initial	
episode.	If	the	patient	was	discharged	from	hospital	prior	to	final	follow‐up,	we	
attempted	in	every	case	to	obtain	data	from	the	hospital,	general	practitioner	or	the	
patient	(the	latter	by	a	telephone	call).	
Determination	of	MBL	serum	concentrations	
A	commercially‐available	in	vitro	diagnostic	ELISA	kit	(Sanquin	Blood	Supply;	
Amsterdam,	Netherlands)	was	transferred	onto	the	Meso	Scale	Discovery	
electrochemiluminescence	(ECL)‐based	platform,	undergoing	appropriate	optimization	
prior	to	use.	The	MBL	kit	control	was	used	across	all	plates	to	determine	inter‐plate	
variability	and	a	subsequent	correction	factor	used	for	each	plate.	Final	minimum	
detection	level	(lower	limit	of	detection;	LLOD)	and	minimum	quantification	level	
(lower	limit	of	quantification;	LLOQ)	were	calculated	by	taking	the	mean	values	across	
all	plates.		The	mean	LLOD	and	LLOQ	across	all	plates	were	11.3	and	11.0	ng/μl,	
respectively,	with	overall	median	values	of	491.9	ng/ml	amongst	controls	and	361.8	
ng/ml	in	cases.		Signal	values	ranged	from	only	50‐500	ECL	units,	which	denotes	a	
compressed	signal	range	inherent	with	the	assay.	Since	this	may	have	potentially	limited	
discrimination	of	the	quantitative	values,	data	were	subject	to	binary	categorisation	
based	on	three	previously	used	deficiency	cut‐offs:	50,	100	and	500	ng/ml	[30‐32].	
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Determination	of	MBL2	variants	
A	total	of	nine	variants	lying	in	the	promoter	and	exon	1	were	typed	(Figure	1)	by	either	
pyrosequencing	(PyroMark	Q96	custom	assays,	Qiagen;	rs36014597,	rs7084554,	
rs1800451,	rs1800450,	rs5030737	and	rs10556764)	or	Taqman	SNP	genotyping	
(Applied	Biosystems;	rs7096206,	rs11003125	and	rs11003123).		The	variants	
rs1800451	(C),	rs1800450	(B),	rs5030737	(D),	rs7096206	(X/Y)	and	rs11003125	(H/L)	
were	used	for	haplotype	determination,	whilst	rs10556764,	a	6bp	Ins/Del	in	complete	
linkage	disequilibrium	with	rs7095891	(P/Q),	was	used	as	a	proxy.		Another	recognized	
tagging	marker	for	P/Q	(rs11003123)	was	independently	typed	to	evaluate	the	accuracy	
of	the	pyrosequencing	assays.		
Pyrosequencing	
PCR	optimization	was	conducted	using	20ng	genomic	DNA	and	temperature	gradients	
following	standard	guidelines.	Optimized	products	were	run	on	a	PyroMark	Q96	ID	
following	the	recommended	assay	protocol.	Repeat	samples	and	blanks	were	included	
for	quality	control	(QC)	purposes	and	data	were	analyzed	using	PyroMark	Q96	v.2.5.8	
software.	
Taqman	genotyping	
Reactions	consisted	of	20ng	genomic	DNA,	1x	Taqman	SNP	genotyping	assays,	run	on	an	
Applied	Biosystems	HT	7900	Fast	Real‐Time	PCR	system	(Applied	Biosystems,	USA)	
using	standard	cycling	conditions.	Repeat	samples	and	blanks	were	incorporated	for	QC	
purposes,	and	results	analyzed	using	SDS	software	(version	2.2).	
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Statistical	analysis	
Median	MBL	serum	concentrations	were	compared	for	individual	SNPs	and	haplotypes	
by	the	Mann‐Whitney	U‐test,	and	then	subjected	to	stratification	based	upon	previously	
used	two‐marker	grouping	profiles	termed	high‐	(YA/YA	&	XA/YA),	intermediate‐	
(XA/XA	&	YA/YO)	and	low‐expressing	(XA/YO	&	YO/YO)	genotypes	[32,	33].		
The	effect	of	both	MBL2	genetics	(based	on	stratified	expression	genotypes)	and	serum	
MBL	concentrations	(based	upon	deficiency	cut‐offs)	were	individually	taken	forward	
for	case‐control	comparison	and	sub‐group	analysis	of	cases.	For	the	latter,	this	included	
logistic	regression	for	the	following	outcome	measures:	A)	severity	of	disease,	B)	
duration	of	symptoms	longer	than	10	days,	C)	90‐day	recurrence,	and	D)	30‐day	
mortality.	Covariates	including	demographic	variables,	the	presence	of	PCR	ribotype	
027/NAP/BI1	and	potential	confounders	(immunosuppressive	therapy,	renal	disease	
and	diabetes,	score	on	Charlson	Comorbidity	Index	and	time	delay	between	sample	
testing	positive	and	recruitment)	were	individually	assessed.	Severity	of	disease	was	
assessed	both	as	a	CDI	outcome	and	as	a	baseline	predictor	for	the	other	outcome	
measures.	Statistically	significant	covariates	were	added	to	the	final	regression	model	to	
produce	adjusted	P‐values,	odds	ratios	and	95%	confidence	intervals.	All	analyses	were	
carried	out	using	SPSS	v.20.	
Power	calculations	were	simulated	using	nQuery	Advisor	+	nTerim	2.0.		This	showed	
that	the	power	a	posteriori	was	≥99%	for	the	majority	of	analyses.	However,	for	analysis	
of	30‐day	mortality	and	disease	severity	at	baseline	power	was	lower	(67	&	75%,	
respectively;	Supplementary	Table	2).	
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Results	
Patient	demographics	
CDI	cases	and	AAD	controls	were	demographically	comparable	(Table	1).	However,	
mortality	at	1	year	(35%	versus	18%;	P<0.001)	and	duration	of	diarrhea	symptoms	
(≥10	days	60%	versus	24%;	P<0.0001)	were	significantly	greater	amongst	CDI	cases.	In	
relation	to	medication	history,	9%	(28/308)	and	1%	(2/145)	of	CDI	cases	and	AAD	
controls	had	prior	exposure	to	PPIs	but	not	antibiotics	within	90	days	of	the	
development	of	CDI,	respectively,	with	58%	(180/308)	and	54%	(79/145)	exposed	to	
both	an	antibiotic	and	a	PPI.	Of	CDI	cases,	41%	(127/308)	had	severe	disease	and	38%	
(83/220)	experienced	recurrence	within	90	days.	Twenty‐eight	CDI	cases,	who	had	not	
experienced	any	recurrence	of	symptoms	but	died	within	the	90	day	follow‐up	period,	
could	not	be	included	in	our	analysis	of	recurrence.		
Relationship	of	genotype	with	serum	MBL	concentrations	
Of	the	9	variants	typed	in	the	CDI	cases	and	AAD	controls,	3	were	excluded:	1	SNP	
(rs7084554)	deviated	from	Hardy‐Weinberg	Equilibrium	(HWE	<0.001);	rs11003123	
was	deemed	redundant	due	to	complete	LD	with	the	INS/DEL	polymorphism	
(rs10556764);	and	rs36014597	was	also	in	complete	LD	with	both	rs10556764	and	
rs11003123.		Of	the	6	polymorphisms	analysed,	genotyping	success	rate	was	≥95%.	
Their	minor	allele	frequencies	were	in	line	with	those	reported	in	the	literature	
(Supplementary	Table	3).	For	both	groups,	seven	common	haplotypes	were	derived	
from	the	6	polymorphisms	(Supplementary	Figure	1),	which	is	consistent	with	other	
previous	studies	in	Whites	(Table	2)	[9,	34].	
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Presence	of	the	mutant	allele	for	all	individual	MBL2	variants	had	a	significant	influence	
on	serum	MBL	concentration	across	all	patients,	except	for	the	X	allele	encoded	by	
rs7096206	(P=0.30;	Supplementary	Table	3).	All	the	assembled	MBL2	haplotypes	also	
significantly	impacted	on	serum	concentrations,	except	for	haplotype	LXPA	where	there	
was	no	difference	compared	with	the	overall	median	value	(P=0.34;	Table	2).	Genotypic	
and	haplotypic	analyses	demonstrated	that	the	presence	of	a	variant	allele	for	any	of	the	
three	exonic	variants	(rs1800451,	rs1800450	and	rs5030737)	were	the	major	
contributing	factors	for	lower	MBL	concentrations	(Table	2	and	Supplementary	Table	
3).	
Patients	with	high‐expressing	genotypes	had	a	median	serum	MBL	concentration	of	714	
ng/ml,	compared	with	190	ng/ml	with	intermediate‐expressing	genotypes,	and	32	
ng/ml	with	low‐expressing	genotypes	(P<0.001;	Table	3;	Figure	2A).	The	contribution	of	
the	X	allele,	seemingly	insignificant	when	evaluated	on	an	individual	basis	
(Supplementary	Table	3),	became	apparent	with	a	gradual	decrease	when	compared	
with	the	equivalent	genotypes	containing	the	Y	allele	in	the	rank	order:	XA/YA	<	YA/YA;		
XA/XA	<	XA/YA,	and	XA/YO	<	YA/YO	(Table	3;	Figure	2B).	
MBL	deficiency	cut‐off	points	in	relation	to	haplotype	groups	
In	total	59	(13%),	93	(21%)	and	258	(58%)	patients	had	serum	MBL	concentrations	
below	50,	100	and	500	ng/ml,	respectively.		When	these	data	were	compared	with	the	
“expressing”	genotype	groups,	78%	(42/54)	and	68%	(59/87)	of	those	with	
concentrations	below	50	and	100	ng/ml,	respectively,	were	low	expressors,	compared	
to	28%	(66/236)	of	those	with	a	concentration	less	than	500	ng/ml	(Supplementary	
Table	4).	The	corresponding	figures	for	high	expressors	were	4%	(2/54),	6%	(5/87)	and	
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30%	(70/236),	respectively.		Similarly,	96%	(52/54)	and	93%	(81/87)	of	those	with	
concentrations	below	50	and	100	ng/ml,	respectively,	carried	the	deficient	(O)	
haplotypes,	compared	to	65%	(153/236)	of	those	with	a	concentration	less	than	500	
ng/ml	(Supplementary	Table	4).	Based	on	the	results	above,	only	the	50	and	100	ng/ml	
cut‐offs	were	taken	forward	for	further	analysis,	which	is	consistent	with	previous	
literature	[30,	31].	
Comparison	of	MBL	levels	versus	CDI	disease	outcomes	
Serum	MBL	concentrations	are	shown	in	Supplementary	Table	5.	Analysis	using	both	
<50	and	<100	ng/ml	as	cut‐off	points	to	signify	deficiency	identified	no	significant	
differences	between	CDI	cases	and	AAD	controls	(P=0.79	and	P=0.09,	respectively)	
(Table	4).		Evaluation	of	the	clinical	outcomes	in	CDI	cases	showed	a	significant	
association	with	CDI	recurrence	(P<0.01	for	both;	Table	4)	with	odds	ratios	of	3.18	and	
2.61	at	the	<50	and	<100	ng/ml	cut‐off	points,	respectively.	No	association	was	
identified	with	any	of	the	other	outcomes	including	prolonged	symptoms,	30‐day	
mortality	and	disease	severity	at	baseline	(Table	4).		Despite	the	strong	correlation	
observed	between	genotypes/haplotypes	and	serum	MBL	concentrations	in	this	cohort,	
no	significant	associations	were	identified	between	high‐,	intermediate‐	and	low‐
expressing	genotypes	and	CDI	disease	outcomes	(Supplementary	Table	6).	
There	was	an	inverse	correlation	between	MBL	and	CRP	serum	concentrations	
(Pearson’s	Correlation	Coefficient	R2=‐0.16,	P=0.001;	Supplementary	Figure	2).	No	
significant	correlation	was	identified	with	white	cell	count	(R2=‐0.04,	P=0.44).	
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Discussion	
Studies	evaluating	the	role	of	MBL	in	infectious	and	immune	diseases	have	focused	on	
either	genotype,	phenotype,	or	occasionally	on	both	parameters.		The	latter	approach	is	
preferred	as	it	can	show	discordance	between	genotype	and	phenotype.		This	study	is	
one	of	the	larger	disease‐related	studies	concurrently	investigating	both	
genotypic/haplotypic	variants	and	serum	concentrations	in	Whites	(Supplementary	
Table	1)	and	is	the	first	to	demonstrate	an	association	between	serum	MBL	
concentrations,	but	not	genotype,	and	recurrence	of	CDI	within	90	days	using	two	
distinct	cut‐off	values	for	MBL	deficiency.			
The	mechanistic	basis	of	the	association	is	unclear.		With	other	bacterial	and	viral	
infections,	MBL	is	thought	to	be	capable	of	binding	to	the	cell	surfaces	of	invasive	
pathogens	thereby	stimulating	a	downstream	immune	response.	However,	this	does	not	
seem	to	be	the	case	with	C.	difficile	where	binding	of	MBL	has	been	shown	to	be	low	[24].		
This	suggests	that	MBL	deficiency	does	not	per	se	predispose	to	CDI	and	is	consistent	
with	the	observed	lack	of	difference	in	circulating	concentrations	of	MBL	between	CDI	
cases	and	AAD	controls.		MBL	has	other	functions	including	modulation	of	inflammation	
and	clearance	of	apoptotic	cells	[35].		The	former	may	be	relevant	to	CDI,	where	MBL	
may	be	acting	as	a	modulator	of	the	disease.	Consistent	with	this,	clinical	manifestations	
of	MBL	deficiency	appear	to	be	of	more	relevance	either	in	infants	when	the	immune	
system	is	still	maturing	or	in	susceptible	groups	when	there	is	an	associated	
immunodeficiency	[36],	such	as	in	hospitalized	elderly	patients	or	following	major	
clinical	interventions.	However,	these	are	hypotheses	that	need	further	investigation.	
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Although	MBL	concentrations	remain	relatively	constant	in	individuals	due	to	genetic	
determinants,	MBL	is	known	to	be	a	relatively	modest	acute	phase	reactant	[37].	This	is	
in	sharp	contrast	to	other	acute	phase	proteins	such	as	CRP	whose	concentrations	can	
increase	sharply	by	10	to	1,000‐fold	during	acute	inflammation	[38].	Elevated	CRP	
concentrations	have	previously	been	shown	to	be	associated	with	various	CDI	outcomes	
including	disease	severity	and	recurrence	[25,	39].	Consistent	with	this,	low	MBL	
concentrations	have	been	associated	with	an	increase	in	the	level	of	CRP	[40],	and	with	
our	findings	of	the	association	with	CDI	recurrence	and	inverse	correlation	with	CRP.		In	
keeping	with	the	immunomodulatory	effect	of	MBL,	it	is	known	that	low	concentrations	
lead	to	increased	secretion	of	the	pro‐inflammatory	cytokines	interleukin‐6,	interleukin	
1‐beta	and	TNF	alpha	[40,	41],	all	of	which	have	also	been	shown	to	be	elevated	in	
response	to	CDI	[42,	43].	
The	genetic	architecture	of	the	MBL2	gene	is	complex	(Figure	1)	with	the	existence	of	
numerous	common	functional	polymorphisms	and	haplotypes	(Figure	1,	Tables	2	and	3,	
and	Supplementary	Table	3).	MBL2	haplotype	frequencies	and	the	corresponding	impact	
on	serum	MBL	concentrations	were	in	line	with	those	previously	reported	[9,	13]	(Table	
2).	This	was	also	evident	after	stratification	of	MBL	haplotypes	based	on	previously	
defined	expression	genotypes	[32,	33]	with	carriers	of	low‐expressing	genotypes	
showing	much	lower	serum	MBL	concentrations	than	both	intermediate‐	and	high‐
expressing	genotypes	(32	ng/ml	versus	190	and	714	ng/ml,	respectively;	Table	3).	
Despite	the	strong	association	observed	between	MBL2	genotypes	and	serum	MBL	
concentrations,	and	the	association	between	MBL	concentrations	and	CDI	recurrence,	
there	was	no	association	between	MBL	genotype	and	CDI	outcomes.	Other	studies	have	
also	identified	associations	with	protein	levels,	but	not	with	genotype	(Supplementary	
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Table	1),	highlighting	the	need	to	evaluate	both	MBL	genotype	and	phenotype	in	
infection	and	other	immune	conditions.		The	lack	of	association	between	MBL	genotype	
and	disease	outcome	may	be	due	to	the	incomplete	genetic	penetrance	of	MBL	genetic	
variation	on	phenotype.		In	this	study,	only	78%	and	68%	of	the	low‐expressing	
genotypes	accounted	for	deficient	serum	levels	using	the	cut‐off	values	of	<50	and	<100	
ng/ml,	respectively	(Supplementary	Table	4).	Genetic	heterogeneity	due	to	functionally	
related	genes	such	as	L‐ficolin,	MASP2,	and	surfactant	proteins	may	also	play	a	role,	but	
this	needs	further	investigation.		
Our	study	sought	to	adhere	to	a	stringent	methodology	through	the	use	of	a	relatively	
large	cohort	size	and	extensive	QC,	but	it	is	not	without	its	limitations.	Although	there	is	
less	chance	of	MBL	concentrations	being	confounded	by	infection‐related	events	when	
compared	to	other	response	markers,	one	of	the	clear	drawbacks	of	this	work	is	the	lack	
of	longitudinal	measurements,	which	is	now	being	addressed	in	a	new	prospective	
study.		The	effect	of	proteins	functionally	related	to	MBL,	and	other	markers	of	
inflammation,	and	the	relative	roles	they	play	in	disease	modulation	needs	further	
investigation.		Previous	studies	have	used	various	definitions	for	MBL	deficiency,	with	
commonly	used	cut‐offs	ranging	from	50	[30]	to	500	ng/ml	[32].	It	is	thus	difficult	to	
compare	results	across	different	study	groups	given	the	heterogeneity	of	platforms,	
profile	of	cohorts	and	standards	adopted	for	the	measurement	of	MBL.	Discrepancies	
between	studies	could	be	due	to	low	sample	sizes,	poor	assay	performance	and	
differences	in	techniques	adopted	by	laboratories.	We	have	tried	to	overcome	some	of	
these	limitations	by	evaluating	a	number	of	cut‐off	levels	but	there	is	a	need	for	
international	consensus	and	harmonisation	in	this	area.	
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In	conclusion,	our	data	suggest	that	low	serum	MBL	concentrations	may	act	as	a	
predictor	of	CDI	recurrence.		Further	work	is	needed	to	validate	these	findings	in	an	
independent	cohort	of	patients	and	to	evaluate	the	mechanistic	basis	of	this	association.			
This	area	of	research	would	also	be	advanced	through	consensus	on	definitions	of	
deficiency,	standardisation	of	methods	employed	for	measurement	of	serum	
concentrations,	and	further	evaluation	of	the	genotype‐phenotype	relationships.	
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Table	1	–	Demographics	of	patients	with	Clostridium	difficile	infection	(CDI)	and	
antibiotic‐associated	diarrhea	(AAD)		
Patient’s	characteristics		 CDI	Cases	(n=308)	
AAD	Controls	
(n=145)	
Gender	–	Female,	n	(%)		 177/308	(57) 81/142	(57)	
Age	–	Mean	in	years	(SD)		 70.1	(16.4) 65.0	(17.6)	
BMI	–	Mean	(SD)		 24.6	(6.8) 26.9	(6.9)	
Presence	of	immunosuppression	–	n	(%) 52/307	(17) 35/144	(24)	
Presence	of	renal	comorbidity	–	n	(%)	 157/307	(51) 82/144	(57)	
Presence	of	diabetes	–	n	(%)	 58/307	(19) 39/144	(27)	
Charlson	Comorbidity	score	–	Median	(IQR)	 1.0	(0.0‐2.0) 1.0	(0.0‐2.0)	
Time	delay	(testing/recruitment)	–	Median	(IQR) 3.0	(2.0‐4.0) 2.0	(2.0‐3.0)	
Clinical	Parameters		 	
Duration	of	symptoms	≥10	days	–	n	(%) 175/290	(60)a 32/134	(24)	
All‐cause	mortality	within	30	days	–	n	(%)	 26/305	(9)	 5/142	(4)		
All‐cause	mortality	within	1	yr	–	n	(%) 95/271	(35)b 25/141	(18)	
Disease	severity	at	baseline	–	n	(%)	 127/308	(41) ‐	
Recurrence	within	90	days	–	n	(%)	 83/220	(38) ‐	
	
%:	percentage;	AAD:	Antibiotic‐associated	diarrhea;	BMI:	body	mass	index;	CDI:	Clostridium	difficile	
infection;	IQR:	Interquartile	range;	n:	number;	SD:	Standard	deviation;	
	
Differences	between	case	and	control	groups	were	found	to	be	statistically	significant:	P<0.0001a	&	P<0.001b,	
respectively;	
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Table	2	–	MBL	serum	concentrations	across	MBL2	haplotypes	in	patients	with	Clostridium	difficile	infection	and	antibiotic‐
associated	diarrhea		
	
HYPA	 LYPA	 LYQA	 LXPA	 HYPD	 LYPB	 LYQC	
Presence	of	haplotype	 	
n	(%	frequency)	 213	(29)	 44	(6)	 143	(19)	 170	(23)		 55	(7)	 108	(15)	 11	(1)	
Median,	ng/ml	
(Range)		
612	
(17	‐	3,981)	
587	
(0	‐	2,500)	
529		
(0	‐	3,981)	
428		
(0	‐	2,968)	
157		
(0	‐	815)	
73		
(0	‐	637)	
48		
(0	‐	492)	
Absence	of	haplotype	 	
n	(%	frequency)	 198	(9) 367	(17) 268	(13) 241	(11)	 356	(17) 303	(14) 400	(19)
Median:	Absence,	ng/ml	
(Range)	
171	
(0	–	2,374)	
388	
(0	‐	3,981)	
324	
(0	‐	2,968)	
377	
(0	‐	3,981)	
484	
(0	‐	3,981)	
568	
(0	‐	3,981)	
420	
(0	‐	3,981)	
P‐value*	 <0.001 0.04 <0.001 0.34	 <0.001 <0.001 0.001
	
n:	number;	%	freq.:	Percentage	frequency;	
*P‐values	were	calculated	using	a	Mann‐Whitney	test	comparing	MBL	serum	concentrations	against	the	presence/absence	of	each	individual	haplotype	
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Table	3	–	Median	serum	MBL	concentrations	across	previously	defined	expression	
genotype	groups*	
	
MBL	expression	group	 Genotype n Median	(ng/ml) Combined	median	(ng/ml)
High	 YA/YA	 124 854 714	XA/YA	 113 561
Intermediate	 XA/XA	 16 270 190	YA/YO 91 175
Low	 XA/YO 41 32 32	YO/YO 26 31
	
*Expression	groups	defined	according	to	Eisen	et	al.	2008	[32]	
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Table	4	–	Analysis	of	Clostridium	difficile	infection	disease	outcomes	versus	serum	
MBL	concentration	based	on	deficiency	cut‐offs	of	50	and	100	ng/ml	
	
	 Case	(n=308)	 Control	(n=145)	 P‐value	 OR	(95%	CI)	
	
<50	ng/ml	
	
41	(13%)	 18	(12%)	 0.79a	
	
1.09	(0.58‐2.06)	
<100	ng/ml	
	
70	(23%)	
	
23	(16%)
	
0.09b	
	
1.61	(0.93‐2.79)
	
	 Death	(n=26)	 Survival	(n=276)	 P‐value	 OR	(95%	CI)	
	
<50	ng/ml	
	
3	(12%)	 37	(13%)	 0.78c	
	
1.22	(0.31‐4.82)	
<100	ng/ml	
	
5	(19%)	
	
64	(23%)
	
0.84c	
	
0.88	(0.27‐2.89)
	
	 ≥10	days	(n=174)*	 <10	days	(n=113)*	 P‐value	 OR	(95%	CI)	
	
<50	ng/ml	
	
27	(16%)	 10	(9%)	 0.10d	
	
1.89	(0.88‐4.08)	
<100	ng/ml	
	
42	(24%)	
	
22	(20%)
	
0.35d	
	
1.32	(0.74‐2.35)
	
	 Recurrence	(n=81)*	 Non‐recurrence	(n=136)*	 P‐value	 OR	(95%	CI)	
	
<50	ng/ml	
	
18	(22%)	 13	(10%)	 <0.01e	
	
3.18	(1.40‐7.24)	
<100	ng/ml	
	
29	(36%)	
	
24	(18%)
	
<0.01e	
	
2.61	(1.35‐5.04)
	
	 Severe	(n=125)	 Non‐severe	(n=180)	 P‐value	 OR	(95%	CI)	
	
<50	ng/ml	
	
16	(13%)	 25	(14%)	 0.78d	
	
0.91	(0.46‐1.79)	
<100	ng/ml	
	
29	(23%)	
	
41	(23%)
	
0.93d	
	
1.02	(0.60‐1.76)
	
	
n:	number;	OR:	odds	ratio;	CI:	confidence	interval;	
P‐values	&	ORs	were	calculated	using	univariate	logistic	regression	and	adjusted	for	the	presence	of	
significant	covariates:	a	Age,	BMI,	time	delay	between	testing	positive	and	recruitment	&	the	presence	of	
diabetes;	b	Age,	BMI,	time	delay	between	testing	positive	and	recruitment	&	the	presence	of	diabetes	and	
immunosuppressive	therapy;	c	Age,	BMI,	score	on	Charlson	Comorbidity	Index	and	disease	severity	at	
baseline;	d	No	covariates	were	found	to	be	significant	&	therefore	P‐value	remains	unadjusted;	e	Age;	
* Data regarding duration of symptoms and disease recurrence was unavailable for 18 and 60 of	our	cases,	
respectively.	For	disease	recurrence,	a	further	28	patients	had	died	within	the	follow‐up	period	prior	to	
experiencing	any	recurrent	symptoms	and	therefore	could	not	be	included	in	the	analysis.	Serum	MBL	level	
was	unavailable	for	a	further	3	individuals	who	were	therefore	excluded	from	analysis	across	all	outcomes;	
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FIGURE	LEGENDS	
Figure	1	–	Schematic	representation	of	the	major	MBL2	isoform	and	genetic	
polymorphisms.	Polymorphisms	responsible	for	the	haplotypes	that	ultimately	
determine	MBL	expression	levels	are	indicated	by	the	red	arrows.		*In	this	study,	
rs10556764	(6	bp	deletion)	was	used	as	a	proxy	SNP	for	rs7095891	
Figure	2	–	Median	serum	MBL	concentrations	in	relation	to:	(A)	3‐tier	grouping	
based	on	proposed	expression	profiles;	and	(B)	individual	genotypic	groups	
within	proposed	expression	profiles.	Median	serum	MBL	concentrations	were	
determined	across	previously	defined	expression	profiles:	high	(YA/YA	&	XA/YA),	
intermediate	(XA/XA	&	YA/YA)	and	low	(XA/YO	&	YO/YO).	Median	levels	were	also	
determined	for	the	6	individual	genotypic	groups	across	all	expression	profiles.	
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